245 related articles for article (PubMed ID: 24132809)
1. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.
Widemann BC; Schwartz S; Jayaprakash N; Christensen R; Pui CH; Chauhan N; Daugherty C; King TR; Rush JE; Howard SC
Pharmacotherapy; 2014 May; 34(5):427-39. PubMed ID: 24132809
[TBL] [Abstract][Full Text] [Related]
2. Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.
Scott JR; Zhou Y; Cheng C; Ward DA; Swanson HD; Molinelli AR; Stewart CF; Navid F; Jeha S; Relling MV; Crews KR
Pediatr Blood Cancer; 2015 Sep; 62(9):1518-22. PubMed ID: 25631103
[TBL] [Abstract][Full Text] [Related]
3. Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.
Tuffaha HW; Al Omar S
J Oncol Pharm Pract; 2011 Jun; 17(2):136-40. PubMed ID: 19833686
[TBL] [Abstract][Full Text] [Related]
4. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.
Heuschkel S; Kretschmann T; Teipel R; von Bonin S; Richter S; Quick S; Alakel N; Röllig C; Balaian E; Kroschinsky F; Knoth H; Bornhäuser M; von Bonin M
Cancer Chemother Pharmacol; 2022 Jan; 89(1):41-48. PubMed ID: 34669022
[TBL] [Abstract][Full Text] [Related]
5. Delayed Methotrexate Clearance Despite Carboxypeptidase-G2 (Glucarpidase) Administration in 2 Patients With Toxic Methotrexate Levels.
Wyatt KD; Cooper J; Scott K; Broomall E; Altaf S; Hogan MC; Rodriguez V; Khan S
J Pediatr Hematol Oncol; 2018 Mar; 40(2):152-155. PubMed ID: 29240024
[TBL] [Abstract][Full Text] [Related]
6. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
[TBL] [Abstract][Full Text] [Related]
7. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
Widemann BC; Balis FM; Kim A; Boron M; Jayaprakash N; Shalabi A; O'Brien M; Eby M; Cole DE; Murphy RF; Fox E; Ivy P; Adamson PC
J Clin Oncol; 2010 Sep; 28(25):3979-86. PubMed ID: 20679598
[TBL] [Abstract][Full Text] [Related]
8. [Renal toxicity of high-dose methotrexate].
Garcia H; Leblond V; Goldwasser F; Bouscary D; Raffoux E; Boissel N; Broutin S; Joly D
Nephrol Ther; 2018 Apr; 14 Suppl 1():S103-S113. PubMed ID: 29606256
[TBL] [Abstract][Full Text] [Related]
9. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.
Ramsey LB; Balis FM; O'Brien MM; Schmiegelow K; Pauley JL; Bleyer A; Widemann BC; Askenazi D; Bergeron S; Shirali A; Schwartz S; Vinks AA; Heldrup J
Oncologist; 2018 Jan; 23(1):52-61. PubMed ID: 29079637
[TBL] [Abstract][Full Text] [Related]
10. Glucarpidase for the treatment of life-threatening methotrexate overdose.
Tuffaha HW; Al Omar S
Drugs Today (Barc); 2012 Nov; 48(11):705-11. PubMed ID: 23170306
[TBL] [Abstract][Full Text] [Related]
11. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
12. A second administration of glucarpidase in a different cycle of high-dose methotrexate: Is it safe and effective in adults?
Domingo-González A; Osorio S; Landete E; Monsalvo S; Díez-Martín JL
J Oncol Pharm Pract; 2021 Apr; 27(3):734-738. PubMed ID: 32731844
[TBL] [Abstract][Full Text] [Related]
13. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
Widemann BC; Balis FM; Murphy RF; Sorensen JM; Montello MJ; O'Brien M; Adamson PC
J Clin Oncol; 1997 May; 15(5):2125-34. PubMed ID: 9164227
[TBL] [Abstract][Full Text] [Related]
14. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.
Christensen AM; Pauley JL; Molinelli AR; Panetta JC; Ward DA; Stewart CF; Hoffman JM; Howard SC; Pui CH; Pappo AS; Relling MV; Crews KR
Cancer; 2012 Sep; 118(17):4321-30. PubMed ID: 22252903
[TBL] [Abstract][Full Text] [Related]
15. Treatment of methotrexate intoxication with various modalities of continuous extracorporeal therapy and glucarpidase.
Vilay AM; Mueller BA; Haines H; Alten JA; Askenazi DJ
Pharmacotherapy; 2010 Jan; 30(1):111. PubMed ID: 20030480
[TBL] [Abstract][Full Text] [Related]
16. Glucarpidase following high-dose methotrexate: update on development.
Patterson DM; Lee SM
Expert Opin Biol Ther; 2010 Jan; 10(1):105-11. PubMed ID: 19925307
[TBL] [Abstract][Full Text] [Related]
17. Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.
Fermiano M; Bergsbaken J; Kolesar JM
Am J Health Syst Pharm; 2014 May; 71(10):793-8. PubMed ID: 24780487
[TBL] [Abstract][Full Text] [Related]
18. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
[TBL] [Abstract][Full Text] [Related]
19. Preventing and Managing Toxicities of High-Dose Methotrexate.
Howard SC; McCormick J; Pui CH; Buddington RK; Harvey RD
Oncologist; 2016 Dec; 21(12):1471-1482. PubMed ID: 27496039
[TBL] [Abstract][Full Text] [Related]
20. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
